Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities

American Heart Journal

Volumn 164, Issue 1, 2012, Pages 14-20

  White, William B ^a   Chohan, Saima ^b   Dabholkar, Aruna ^c   Hunt, Barbara ^c   Jackson, Robert ^c  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; FEBUXOSTAT;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DRUG SAFETY; FOLLOW UP; GOUT; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; UNSTABLE ANGINA PECTORIS;

ALLOPURINOL; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; GOUT; GOUT SUPPRESSANTS; HUMANS; PROSPECTIVE STUDIES; THIAZOLES;

EID: 84863717857     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.04.011     Document Type: Article

References (15)

1. Kim KY, Ralph Schumacher H, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593-617. (Pubitemid 36805619)
2. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12:223-34.
3. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900. (Pubitemid 47300913)
4. Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168:1104-10. (Pubitemid 351749228)
5. Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in subjects at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008;58:623-30. (Pubitemid 351294901)
6. Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13. (Pubitemid 29310011)
7. Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary disease: the Framingham Study. J Clin Epidemiol 1988;41:237-42. (Pubitemid 18069583)
8. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000;283:2404-10. (Pubitemid 30257539)
9. U.S. Food and Drug Administration. FDA announces new recommendations on evaluating cardiovascular risk in drugs intended to treat type 2 diabetes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116994.htm. Last accessed May 29, 2011.
10. Schumacher Jr HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8.
11. Schumacher Jr HR, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009;48:188-94.
12. Becker MA, Schumacher Jr HR, Wortmann RL, et al. Febuxostat compared with allopurinol in subjects with hyperuricemia and gout. N Engl J Med 2005;343:2450-61. (Pubitemid 41781828)
13. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
14. Borer JS, Pouleur H, Abadie E, et al. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J 2007;28:1904-9. (Pubitemid 47236658)
15. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.